Curanex Pharmaceuticals Issues Q1 2026 Business Update on Lead Drug Phyto‑N

What Happened

• Curanex Pharmaceuticals Inc. filed a Form 8-K on May 14, 2026 (Item 7.01) to disclose a press release providing a business update for the first quarter of 2026.
• The release highlights the company’s continued progress with its lead drug candidate, Phyto‑N. The press release is attached to the 8‑K as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: May 14, 2026 (Form 8‑K, Regulation FD Disclosure).
• Subject: Q1 2026 business update emphasizing progress with Phyto‑N (lead drug candidate).
• Disclosure method: press release attached as Exhibit 99.1 to the 8‑K.

Why It Matters

• The 8‑K provides a timely, public update under Regulation FD so all investors receive the same information about Curanex’s development progress.
• Progress updates on a company’s lead drug candidate are material for biotech investors because they can affect timelines, valuation expectations, and future financing or partnership needs.
• Investors should review the attached press release (Exhibit 99.1) for any operational or clinical details and monitor future filings or announcements for more specific data or milestones.